Earnings8-K
Results of Operations and Financial Condition
Show detailsHide details
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
IMCR
Immunocore Holdings Plc
A British biotechnology company that engineers a novel class of immunotherapies that harness the body's T cells to fight disease, using its ImmTAX platform. Its first approved medicine, KIMMTRAK, treats a rare eye cancer called uveal melanoma and was the first T-cell receptor therapy ever approved. The company grew out of T-cell research at the University of Oxford, spun out in 2008, and its platform name stands for "Immune Mobilizing Monoclonal TCRs Against X disease."
ADRUnderlying: IMCRCUSIP: 45258D105HealthcareGB1 holder
Immunocore Holdings plc Sponsored ADR